Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (12 quarters reported)
$82.2M in Q4 2015 → $8.91M now. Hover for any quarter.
As reported for the quarter ended September 30, 2018. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Adma Biologics, Inc. | 100.0% | Unchanged | 1,433,304 | $8.9M |
| MT Mabvax Therapeutics Holdings, Inc. | 0.0% | Unchanged | 8,903 | $4K |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended September 30, 2018 · filed October 24, 2018
No position changes this quarter.
quarter ended June 30, 2018 · filed August 09, 2018
No position changes this quarter.
quarter ended March 31, 2018 · filed April 20, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| JT Juno Therapeutics, Inc. | Exited | −1,864,174 | −$85.2M | — |
| MT Mabvax Therapeutics Holdings, Inc. | Exited | −26,708 | −$19K | — |
| MT Mabvax Therapeutics Holdings, Inc. | New | +8,903 | +$13K | 0.2% |
quarter ended December 31, 2017 · filed February 13, 2018
No position changes this quarter.
quarter ended September 30, 2017 · filed October 30, 2017
No position changes this quarter.
quarter ended June 30, 2017 · filed August 08, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| JT Juno Therapeutics, Inc. | Trimmed | −304,427 | −$9.1M | 91.3% |
quarter ended March 31, 2017 · filed May 11, 2017
No position changes this quarter.
quarter ended December 31, 2016 · filed February 13, 2017
No position changes this quarter.
Loading...
